ROZLYTREK
PeakNDAORALCAPSULEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 39m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROZLYTREK (entrectinib) is an oral small-molecule tyrosine kinase inhibitor targeting TRK, ROS1, and ALK fusion proteins in patients with solid tumors. It is indicated for NTRK, ROS1, or ALK fusion-positive cancers where surgical resection would cause severe morbidity, with approval based on FDA-approved companion diagnostics. The drug crosses the blood-brain barrier effectively, enabling treatment of central nervous system metastases.
$0.016BPart D
PeakPeak lifecycle stage suggests mature commercial infrastructure with stable field operations; modest Part D spend of $16M indicates niche market with limited team expansion near-term.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ROZLYTREK careers span niche oncology roles focused on rare genetic subsets, demanding expertise in companion diagnostics, precision medicine marketing, and healthcare provider education. Career growth depends on indication expansion and competitive defense; the 0 linked jobs suggest limited active hiring, typical for peak-stage specialty drugs with established infrastructure.
Brand Manager
Worked on ROZLYTREK at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.